To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Biopsy-proven idiopathic membranous nephropathy

• Nephrotic syndrome with proteinuria (> 4 g/day) and serum albumin < 30 g/dl

• Age over 18 with informed consent

Exclusion Criteria:

• Patient with abnormal liver function tests

• Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days,

• Active/serious infection,

• Patient with hepatitis B surface antigen or who is hepatitis C antibody positive